Literature DB >> 23153531

Epigenetic therapy leaps ahead with specific targeting of EZH2.

Ari Melnick1.   

Abstract

The Polycomb epigenetic silencing protein EZH2 is affected by gain-of-function somatic mutations in B cell lymphomas. Two recent reports describe the development of highly selective EZH2 inhibitors and reveal mutant EZH2 as playing an essential role in maintaining lymphoma proliferation. EZH2 inhibitors are thus a promising new targeted therapy for lymphoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 23153531      PMCID： PMC3732786          DOI： 10.1016/j.ccr.2012.10.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  A decade of exploring the cancer epigenome - biological and translational implications.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

2.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Authors:  Irina Velichutina; Rita Shaknovich; Huimin Geng; Nathalie A Johnson; Randy D Gascoyne; Ari M Melnick; Olivier Elemento
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

3.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

5.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

6.  Polycomb group protein ezh2 controls actin polymerization and cell signaling.

Authors:  I-hsin Su; Marc-Werner Dobenecker; Ephraim Dickinson; Matthew Oser; Ashwin Basavaraj; Raphael Marqueron; Agnes Viale; Danny Reinberg; Christoph Wülfing; Alexander Tarakhovsky
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

Review 7.  Aberrations of EZH2 in cancer.

Authors:  Andrew Chase; Nicholas C P Cross
Journal:  Clin Cancer Res       Date:  2011-03-02       Impact factor: 12.531

8.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.

Authors:  Rita Shaknovich; Leandro Cerchietti; Lucas Tsikitas; Matthias Kormaksson; Subhajyoti De; Maria E Figueroa; Gianna Ballon; Shao Ning Yang; Nils Weinhold; Mark Reimers; Thomas Clozel; Karin Luttrop; Tomas J Ekstrom; Jared Frank; Aparna Vasanthakumar; Lucy A Godley; Franziska Michor; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

9.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement.

Authors:  I-Hsin Su; Ashwin Basavaraj; Andrew N Krutchinsky; Oliver Hobert; Axel Ullrich; Brian T Chait; Alexander Tarakhovsky
Journal:  Nat Immunol       Date:  2002-12-23       Impact factor: 25.606

10.  Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Authors:  Ryan D Morin; Nathalie A Johnson; Tesa M Severson; Andrew J Mungall; Jianghong An; Rodrigo Goya; Jessica E Paul; Merrill Boyle; Bruce W Woolcock; Florian Kuchenbauer; Damian Yap; R Keith Humphries; Obi L Griffith; Sohrab Shah; Henry Zhu; Michelle Kimbara; Pavel Shashkin; Jean F Charlot; Marianna Tcherpakov; Richard Corbett; Angela Tam; Richard Varhol; Duane Smailus; Michelle Moksa; Yongjun Zhao; Allen Delaney; Hong Qian; Inanc Birol; Jacqueline Schein; Richard Moore; Robert Holt; Doug E Horsman; Joseph M Connors; Steven Jones; Samuel Aparicio; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330
  10 in total
  12 in total

1.  Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.

Authors:  Yu Kong; Chunbo Ai; Feng Dong; Xianyou Xia; Xiujuan Zhao; Chao Yang; Chunsheng Kang; Yan Zhou; Qian Zhao; Xiujing Sun; Xudong Wu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

2.  C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels.

Authors:  Yi Shi; Hong-Lei Ma; You-Wen Zhuang; Xiao-Xi Wang; Yi Jiang; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2019-06-11       Impact factor: 6.150

Review 3.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Notch Represses Transcription by PRC2 Recruitment to the Ternary Complex.

Authors:  Xiaoqing Han; Prathibha Ranganathan; Christos Tzimas; Kelly L Weaver; Ke Jin; Luisana Astudillo; Wen Zhou; Xiaoxia Zhu; Bin Li; David J Robbins; Anthony J Capobianco
Journal:  Mol Cancer Res       Date:  2017-06-05       Impact factor: 5.852

5.  Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

Authors:  Lixin Wan; Kexin Xu; Yongkun Wei; Jinfang Zhang; Tao Han; Christopher Fry; Zhao Zhang; Yao Vickie Wang; Liyu Huang; Min Yuan; Weiya Xia; Wei-Chao Chang; Wen-Chien Huang; Chien-Liang Liu; Yuan-Ching Chang; Jinsong Liu; Yun Wu; Victor X Jin; Xiangpeng Dai; Jianfeng Guo; Jia Liu; Shulong Jiang; Jin Li; John M Asara; Myles Brown; Mien-Chie Hung; Wenyi Wei
Journal:  Mol Cell       Date:  2018-01-18       Impact factor: 17.970

Review 6.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

Review 7.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

Review 8.  Chromatin targeting drugs in cancer and immunity.

Authors:  Rab Prinjha; Alexander Tarakhovsky
Journal:  Genes Dev       Date:  2013-08-15       Impact factor: 11.361

9.  Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.

Authors:  Richard L Momparler; Sylvie Côté; Louise F Momparler; Youssef Idaghdour
Journal:  Clin Epigenetics       Date:  2014-10-01       Impact factor: 6.551

10.  Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration.

Authors:  F Crea; L Sun; L Pikor; P Frumento; W L Lam; C D Helgason
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.